Armodafinil (Nuvigil®) is an eugeroic drug made by Cephalon, FDA-approved 6/15/2007. Clinical trials for its use in bipolar disorder, cognition in schizophrenia, excessive fatigue in Parkinson's & cancer, begin. Patent expires 2023.
Armodafinil From Wikipedia, the free encyclopedia Jump to: navigation, search Armodafinil Systematic (IUPAC) name (-)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide Identifiers CAS number 68693-11-8 ATC code N06BA07 PubChem ? Chemical data Formu
Weak willpower & procrastination caused by dopamine hypofunction is one of those neurological deficiencies which effort alone can't overcome. Happily, in our transhuman paradise, even the most lethargic spirit can move mountains.
Darwinian evolution has powerfully favoured the growth of ever more diverse, excruciating, but also more adaptive varieties of psychophysical pain. Its sheer nastiness effectively spurs and punishes the living vehicles of genetic replicators.
Here's just one: Even talking about posthuman psychological superhealth is morally frivolous. Another? Promoting superhappiness may lead to what one may call, informally, "inappropriate" behavioural responses.
Full-text, online textbook discussing various pharmaceutical, neutraceutical, and lifestyle interventions for enhancing life by facilitating our efforts to reach our fullest potential.
Modafinil induces wakefulness, but its dopamine-releasing action in the nucleus accumbens is weak and dose-dependent; no likelihood of euphoric response ('abuse potential').
A single protein in the brain influences arousal of despair, according to new study in mice. Brain biopsies revealed that mice trying hardest to escape shocks had highest levels of delta-FosB - which may also help humans avoid hopelessness & helplessness.
Unlike conventional stimulants, no anxiety, agitation and insomnia; selectively stimulates brain's adrenergic receptors for norepinephrine (noradrenaline), a neurotransmitter linked to alertness, learning, and memory.
T. Itatsu, A. Nagahara, M. Hojo, A. Miyazaki, T. Murai, M. Nakajima, и S. Watanabe. Internal medicine (Tokyo, Japan), 50 (7):
713-7(января 2011)JID: 9204241; 0 (Serotonin Uptake Inhibitors); 2011/04/01 epublish; ppublish; Confusió absoluta entre cas-control i exposats-no exposats<br/><br/><br/>Tipus d'estudis.